Committee Composition

  Audit Compensation Nominating and Governance
Kent Kresa Chairman of the Board   Committee Chair for Compensation Committee Member of Nominating and Governance Committee
Ronald Consiglio Independent Director Committee Chair for Audit Committee   Member of Nominating and Governance Committee
Michael Friedman, M.D. Independent Director   Member of Compensation Committee Committee Chair for Nominating and Governance Committee
David H. MacCallum Independent Director Member of Audit Committee    
Henry L. Nordhoff Independent Director Member of Audit Committee    

Henry L. Nordhoff has been one of our directors since March 2005. He has served as a director of BioTime, Inc. since June 2013 and as a director of Asterias Biotherapeutics, Inc. since October 2013. Mr. Nordhoff retired as Chairman of the Board of Gen-Probe Incorporated, a clinical diagnostic and blood screening company, at the end of 2011, after serving as its Chairman since September 2002. He also served as Chief Executive Officer and President of Gen-Probe from July 1994 until May 2009. Prior to joining Gen-Probe, he was President and Chief Executive Officer of TargeTech, Inc., a gene therapy company that was merged into Immune Response Corporation. Prior to that, Mr. Nordhoff was at Pfizer, Inc. in senior positions in Brussels, Seoul, Tokyo and New York. He received a B.A. in international relations and political economy from Johns Hopkins University and an M.B.A. from Columbia University.

Holdings: 103,426 shares     View Transactions
James S. Shannon Independent Director   Member of Compensation Committee  
Chair of the Board = Chair of the Board Committee Chair = Chair Committee Member = Member Independent Director = Independent Director   = Financial Expert

Stock transaction information provided by EDGAR Online. MannKind Corporation makes no representation or warranty with respect to any of the information contained herein, takes no responsibility for supplementing, updating or correcting any such information and shall have no liability with respect to any such information. This listing does not include derivatives, such as stock option grants or shares purchased through an employee stock purchase plan. For recent transactions, including derivative transactions, see our Section 16 SEC filings page.



Price: 2.02

Change:   0.00 (0.000%)

Volume: N/A

Data as of
09/19/2017 04:00 PM ET .
Minimum 20 minute delay.

Refresh Quote >


Learn more about MannKind's offices in the United States

Learn More